Trial Profile
A Double-blind, Randomised, Placebo Controlled Study With Two Sequential Two-way Cross-over Parts to Demonstrate That the Influence of Pramipexole up to 4.5 mg Daily on the QT Interval of the ECG in Healthy Male and Female Volunteers is Comparable With Placebo, With a Positive Control (Two-way Cross-over Moxifloxacin Versus Placebo)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Oct 2014
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Gilles de la Tourette's syndrome; Myoclonus; Parkinson's disease; Restless legs syndrome
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 17 Oct 2014 New trial record